EP 3558316 A1 20191030 - USE OF CHYMASE INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS, POST-OPERATIVE FIBROSIS AND DISEASES WHICH ARE CHARACTERIZED BY FIBROSIS FORMATION
Title (en)
USE OF CHYMASE INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS, POST-OPERATIVE FIBROSIS AND DISEASES WHICH ARE CHARACTERIZED BY FIBROSIS FORMATION
Title (de)
VERWENDUNG VON CHYMASEINHIBITOREN ZUR BEHANDLUNG VON ENDOMETRIOSE, POST-OPERATIVER FIBROSE UND ERKRANKUNGEN DIE DURCH FIBROSEBILDUNG GEKENNZEICHNET SIND
Title (fr)
UTILISATION D'INHIBITEURS DE LA CHYMASE POUR LE TRAITEMENT DE L'ENDOMÉTRIOSE, DE LA FIBROSE POST-OPÉRATOIRE ET DES MALADIES CARACTÉRISÉES PAR LA FORMATION D'UNE FIBROSE
Publication
Application
Priority
- EP 16205339 A 20161220
- EP 2017082569 W 20171213
Abstract (en)
[origin: CA3047448A1] The invention relates to the use of by cyclically-substituted uracil derivatives, on their own or in combination with other active substances, for the treatment and/or prophylaxis of illnesses, in particular for the treatment and/or prophylaxis of inflammatory and fibrotic diseases, for the treatment of endometriosis, of endometriosis-associated fibrosis, of adenomyosis, and of pain associated with an endometriotic disease, and of post-operative peritoneal fibrosis and adhesion formation.
IPC 8 full level
A61K 31/513 (2006.01); A61P 15/00 (2006.01)
CPC (source: EP IL KR US)
A61K 31/506 (2013.01 - IL US); A61K 31/513 (2013.01 - EP IL KR); A61K 31/536 (2013.01 - IL US); A61P 5/30 (2017.12 - EP IL); A61P 15/00 (2017.12 - EP IL); A61P 15/02 (2017.12 - EP IL KR); A61P 41/00 (2017.12 - EP IL US)
Citation (search report)
See references of WO 2018114514A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
EP 3338780 A1 20180627; AU 2017381324 A1 20190704; BR 112019012503 A2 20200414; CA 3047448 A1 20180628; CL 2019001713 A1 20191115; CN 110072527 A 20190730; EA 201991292 A1 20191230; EP 3558316 A1 20191030; IL 266823 A 20190731; IL 266823 B 20220301; JO P20190149 A1 20190619; JP 2020502272 A 20200123; KR 20190098984 A 20190823; MA 47067 A 20191030; MX 2019007377 A 20190918; PH 12019501409 A1 20200309; SG 10202106586T A 20210729; TW 201827053 A 20180801; TW I753070 B 20220121; UA 124848 C2 20211201; US 11266646 B2 20220308; US 2019381040 A1 20191219; WO 2018114514 A1 20180628
DOCDB simple family (application)
EP 16205339 A 20161220; AU 2017381324 A 20171213; BR 112019012503 A 20171213; CA 3047448 A 20171213; CL 2019001713 A 20190619; CN 201780078622 A 20171213; EA 201991292 A 20171213; EP 17818103 A 20171213; EP 2017082569 W 20171213; IL 26682319 A 20190522; JO P20190149 A 20170616; JP 2019553638 A 20171213; KR 20197018728 A 20171213; MA 47067 A 20171213; MX 2019007377 A 20171213; PH 12019501409 A 20190619; SG 10202106586T A 20171213; TW 106144698 A 20171220; UA A201908579 A 20171213; US 201716471928 A 20171213